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Topical NSAIDs in Prevention of
Postcataract Macular Edema
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Abstract
Postoperative macular edema is considered one cause of diminished vision after
cataract surgery. It was approved that inflammatory mediators especially prosta-
glandins play a key role in macular edema formation especially in the presence of
risk factors that affect blood-retinal barrier such as diabetes, uveitis, tear of poste-
rior capsule, and vitreous loss. So, anti-inflammatory medications like corticoste-
roids and NSAIDs are the cornerstone of macular edema managements. In spite of
using corticosteroids as gold standard for treatment of ocular inflammation, they
cannot be used for prolonged period due to associated adverse effects. Lastly, there
were many studies about benefits of NSAIDs in management and prevention of
macular edema to avoid the side effects of corticosteroids.
Keywords: NSAIDs, macular edema, phacoemulsification, cataract, blood-retinal
barrier
1. Introduction
Macula is an important part of the retina, which is responsible for color vision,
contrast sensitivity, sharp vision, communications and interpersonal relationships [1].
Macular thickening is well-known postoperative complication after cataract
surgery, even with uncomplicated small incision phacoemulsification surgery. Sub-
clinical cystoid macular edema (CME) is diagnosed with fluorescein angiography as
leakage from perifoveal dilated capillaries without visual acuity affection [2].
Although fluorescein angiography is considered gold standard for diagnosis of
macular edema, quantification of fluorescein leakage is difficult. Optical coherence
tomography (OCT) nowadays has an upper hand in diagnosis of macular edema
because of its advantages as a noninvasive device and can detect macular edema
quantitatively and qualitatively [3].
Clinical CME can be identified on biomicroscopic examination and is associated
with decreased visual acuity [4].
The pathogenesis of CME is disruption of blood-retinal barrier (BRB) by
inflammatory mediators generated through several cascades as a result of surgical
trauma to iris, ciliary body, or lens epithelial cells. Also, preexisting ocular condi-
tions such as diabetes, hypertension, and uveitis, which affect BRB, can increase
risk of CME [5].
The blood-retinal barrier in diabetic eyes is impaired to a variable degree, which
plays a role in development of postoperative CME. CME in diabetic patients is
affected by many factors including duration, severity of the disease, presence of
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retinopathy, and previous treatment with photocoagulation [6]. Total ophthalmic
payments were documented to be 47% higher in patients who developed postoper-
ative CME [7]. So, prophylactic prevention or even decreased CME severity is cost
savings, particularly among diabetic patients.
2. Macular anatomy and physiology
Being themain part of clear vision, the macula is located in the heart of the retina
between upper and lower arcades measured about 4.5–6mm in diameter. It can be
divided into central fovea, surrounded by parafovea and outer perifovea (Figure 1) [8].
• Retinal vascular plexus was described simply into two planes: inner one at
ganglion cell layer and outer plexus at inner nuclear layer [9] (Figure 2).
Figure 1.
Parts of the macula from inside to outside: foveola, fovea, parafovea, and perifovea [8].
Figure 2.
Vascular plexus position in layers of retina: inner vascular plexus in ganglion cell layer and deep vascular
plexus in inner nuclear layer [9].
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• As a whole, the retina blood supply is divided into outer part supplied by
choriocapillaris and inner part supplied by retinal vascular plexus branch of
posterior ciliary arteries [10].
3. The blood-retinal barrier
The blood-retinal barrier (BRB) is a barrier that physiologically establishes and
maintains specific substrate and ion concentrations to allow proper neural function.
BRB regulates flux of substances in retina such as ion, protein, and water and also
regulates infiltration of immune competent cells and blood toxins. BRB is formed at
two levels, inner and outer BRB. The inner one is composed of tight junctions
between retinal vascular endothelial cells. The outer barrier is composed of tight
junction between retinal pigment epithelium cells [11].
Pericytes secrete angiopoietin 1, which induces tight junction protein expression
to support endothelial cells barrier [12].
3.1 Tight junction
Tight junction is mainly apical junctional complex, which has a barrier function
against solute flux and movement of proteins and lipids into retinal parenchyma.
This junction is showed as transmembrane proteins and junctional adhesion mole-
cule (JAM) [13].
3.2 Adherens junction
Adherens junction is second barrier beneath the tight junction. This junction
is important for development of the barrier as it affects formation of tight
junction [14].
Tight junction: Transmembrane proteins claudins, occludin, and junctional adhe-
sion molecule (JAM) connected with scaffolding protein ZO to actin.
Adherens junction: Vascular endothelial (VE) cadherin connected to actin
through complex of β-catenin, α-catenin, and vinculin.
4. Pathophysiology
The macula is responsible for central 30 degrees of sharp vision with color
vision, interpersonal relationships, communications, and contrast sensitivity [1].
The retina is very sensitive to fluctuation in blood oxygen levels and intraocular
changes, as it consumes oxygen more than other tissues, being highly active tissue.
Microchanges not felt by patient visual acuity are also not seen by inspection
ophthalmoscopy examination [15].
It has been reported that clinical affection due to CME after uneventful
phacoemulsification is between 0 and 9%. Furthermore, clinical affection between
9.1 and 20.4% with angiographic leakage is reported [16]. Interruption of blood-
retinal barrier is the most accepted explanation of postoperative macular edema,
which causes macular thickening. Surgical trauma disrupts the blood-aqueous bar-
rier, release of prostaglandins, and increase of perifoveal capillaries’ permeability of
liquid in extracellular spaces, which cause macular thickening and CME [17]. The
pathophysiology of these macular changes may be considered consecutively as
follows: (1) release of inflammatory mediators into anterior chamber produced by
surgical procedures; (2) removal of normally lens barrier, which separate posterior
3
Topical NSAIDs in Prevention of Postcataract Macular Edema
DOI: http://dx.doi.org/10.5772/intechopen.82321
segment from anterior segment; (3) local effect of inflammatory mediators on
macular area; and (4) anterior displacement of vitreous leading to increase traction
on macula [18].
Recently, being noninvasive, OCT has been established to be the main method
for examining retinal architecture [19]. OCT can measure microhistological retinal
changes in difference to fluorescein angiography, which detects it as a leakage that
cannot be detected by biomicroscopy [20]. It was reported that subclinical increase
in retinal thickness and volume can be found in the early course postoperatively at
4 weeks after phacoemulsification [21].
5. Nonsteroidal anti-inflammatory drugs
Surgical trauma stimulates arachidonic acid cascade, which stimulates phospholi-
pase A2 enzyme to release arachidonic acid frommembrane phospholipids and pro-
duces inflammatory mediators including prostaglandins (PGs) and leukotriene by
activation of cyclooxygenase (COX) enzymes. COX-1 and COX-2 isoforms are believed
to be the primarymediator of ocular inflammation. PG is an important mediator of
postoperative complications, associated with symptoms including pain, ciliary injec-
tion, cystoid macular edema, impaired vision, and intraoperative miosis [22].
So, treatment of ocular inflammation depends mainly on stopping of arachidonic
cascades by corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs).
Corticosteroids inhibit the activity of phospholipase A2 enzyme, but NSAIDs inhibit
PGs synthesis irreversibly and nonspecifically by direct inhibition of COX-1 and
COX-2 activity [23] (Figure 3).
5.1 Corticosteroids
In spite of using corticosteroids as gold standard for treatment of ocular inflam-
mation, they cannot be used for prolonged period due to associated adverse effects.
Figure 3.
Action of corticosteroid and NSAIDs on arachidonic acid cascade [23].
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Side effects of corticosteroids include increased susceptibility to infections as a
result of suppression of host immune response, retardation of corneal wound
healing, and increased intraocular pressure (IOP) [24].
5.2 Nonsteroidal anti-inflammatory drugs
NSAIDs are considered as safety option used for treatment of ocular inflamma-
tion. NSAIDs inhibit COX activity patently by several chemically heterogeneous
classes [25].
Currently, the uses of topical NSAIDs in ophthalmology to reduce pain and
discomfort after cataract and refractive surgery prevent intraoperative miosis dur-
ing cataract surgery and manage postoperative inflammation (Table 1) and are also
reported to have a role in prevention of CME after cataract surgery [25, 27].
NSAIDs have beneficial effects over corticosteroids including analgesia effect,
maintaining pupillary dilatation if used preoperatively (Figure 4), and also reduce
the risk of secondary infections and increased IOP [25].
5.3 Pharmacokinetics
Diclofenac: Plasma levels reached (10 ng/mL) during a 4 hours period after
instillation of two drops in each eye [29].
Flurbiprofen: No information about systemic absorption was approved.
Ketorolac: The use of ketorolac in 26 patients with one drop in each eye three
times daily resulted in 5/26 (= 19.2%) with detectable plasma level of ketorolac
(10.7–22.5 ng/mL) after 10 days.
Bromfenac: After topical administration, plasma level is expected to be below the
detectable limit (50 ng/mL).
Nepafenac: It is an inactive prodrug, which penetrates corneal epithelium and is
converted by ocular tissue hydrolases to active form amfenac. Plasma levels of
bromfenac and amfenac were detected 2–3 hours in most patients after installation
of nepafenac in both eyes but with low plasma level.
Drug Indications
Diclofenac
sodium
Management of postoperative inflammation in patients after cataract extraction
Decrease of pain and photophobia in patients after corneal refractive surgery
Flurbiprofen
sodium
Maintenance of intraoperative pupil dilatation
Ketorolac
tromethamine
(0.5%) Temporary relief of ocular itching associated with seasonal allergic
conjunctivitis
Management of postoperative inflammation in patients after cataract
extraction
(0.4%) Decrease of ocular pain and burning/stinging in patients undergoing
corneal refractive surgery
(0.45%)
(0.5%)
Reduction of ocular pain and inflammation associated with/following
cataract surgery
Bromfenac
sodium
Management of postoperative inflammation and pain after cataract surgery
Nepafenac Management of inflammation and pain associated with cataract surgery
Table 1.
Ophthalmic NSAIDs’ FDA-approved indications [26].
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5.4. Limitation of NSAIDs
Topical NSAIDs contain some warnings, which include the following:
1. Prolonged bleeding time [30].
2. Cross-sensitivity with phenyl acetic acid derivatives, acetylsalicylic acid, and
other NSAIDs [31].
3.Delay wound healing mainly if used in combination with corticosteroids [32].
4.Topical NSAIDsmay cause ocular surface toxicity especially in patients having dry
eye syndrome, corneal denervation, corneal epithelial defects, or diabetes [33].
6. Discussion
In the last few years, there were many studies using NSAIDs to prevent postop-
erative CME in different situations. In Table 2, some studies focus on the effect of
NSAIDs in prevention of postoperative CME in diabetic patients. All of them
approved significant low macular thickening in diabetic patients receiving NSAID
bromfenac only [34], classical postoperative steroid regimen in addition of
nepafenac [35] or either nepafenac or ketorolac with classical postoperative steroid
regimen [28].
Other studies documented the effect of NSAIDs in a mixed population
(nondiabetic and diabetic patients) without cystoid macular edema preoperatively
and with no predisposing factors for developing cystoid macular edema (Table 3).
Some studies documented that topical steroid medication may not be absolutely
essential after uneventful cataract surgery [37, 44]. Topical nonsteroidal started
1 day before surgery and continued for 1 month by Almeida et al. [37], while
Nishino et al. [44] started medication postoperatively and continued for 1 month.
On the other hand, many studies approved the significant importance of topical
NSAIDs in prevention of macular edema [36, 38–43, 45, 46]. topical ketorolac had
more effect in decreasing macular edema than prednisolone only, if started 2 days
before surgery and continued for 1 month postoperatively in combination with
Figure 4.
Comparing pupil poor dilatation in control group (A) and full dilated pupil with NSAIDs (B) [28].
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Study Number Groups Follow-
up
Conclusion
Endo
et al.
[34]
62 (26 patients
with
nonproliferative
diabetic
retinopathy)
1. Bromfenac (n = 31)
(16 with NPDR)
2. Steroidal solution
(n = 31) (11 with
NPDR)
OCT
6 weeks
The perifoveal values were
significantly lower in the
bromfenac group
Singh
et al.
[35]
263 patients with
nonproliferative
diabetic
retinopathy
1. Nepafenac (n = 125)
2. Vehicle (n = 126)
OCT
90 days
Significantly lower percentage
of patients in the nepafenac
group developed macular
edema
Alnagdy
et al.
[28]
80 without
diabetic
retinopathy
1. Placebo group +
prednisolone
2. Nepafenac
0.1% + prednisolone
3. Ketorolac
0.4% + prednisolone
OCT
3 months
Perioperative NSAIDs reduce
the frequency and severity of
CME in diabetic eyes following
cataract surgery
Table 2.
Clinical trials using ophthalmic NSAIDs to prevent postoperative macular edema in diabetic patients
without cystoid macular edema preoperatively and with no predisposing factors for developing cystoid macular
edema.
Study Number Groups Follow-up Conclusion
Almeida
et al. [36]
106 1. Prednisolone 1%
2. Prednisolone
1% + ketorolac 0.5%
OCT
1 month
After cataract surgery,
ketorolac 0.5%
effectively decreases
postoperative macular
edema
Almeida
et al. [37]
193 1. Prednisolone 1%
2. Prednisolone
1% + nepafenac 0.1%
3. Prednisolone
1% + ketorolac 0.5%
(1 day before surgery for 1
month postoperative)
OCT
1 month
There was no difference
in macular volume
between the placebo,
ketorolac, and
nepafenac
Cable et al.
[38]
20 diabetic
patients
without
edema could
be enrolled
1. Prednisolone +
bromfenac
2. Prednisolone +
nepafenac
OCT
6 weeks
Postoperative
bromfenac showed a
trend toward improved
vision, less retinal
thickening, and more
stable macular volumes
overall
Cervantes-
Coste et al.
[39]
60 excluding
proliferative
DR, macular
edema,
uncontrolled
DM
1. Dexamethasone
2. Dexamethasone +
nepafenac
OCT
6 weeks
Nepafenac has a rule in
reducing macular
edema after cataract
surgery and in
maintaining
intraoperative
mydriasis
Rossetti
et al. 1996
[40]
88 1. Diclofenac
2. Placebo
Ocular
inflammation
and FFA and
visual acuity
6 months
Diclofenac eye drops
effectively reduced
incidence of
angiographic CME and
ocular inflammation
after cataract surgery
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prednisolone had more effect in decreasing macular edema in comparison to post-
operative topical prednisolone alone [36]. Wittpenn et al. approved that starting
ketorolac 1 hour before surgery had significant effects in preventing macular edema
[46]. Cervantes-Coste et al. documented that diclofenac effectively maintains
mydriasis and decreases macular thickness [39]. Also, diclofenac eye drops in Ros-
setti et al. effectively reduced incidence of angiographic CME and ocular inflam-
mation after cataract surgery [40], while Miyake et al. suggested that diclofenac
effectively decreases CME in comparison to fluorometholone [41] and also
approved its effect in preventing chronological change in choroidal blood flow and
disruption of the blood-aqueous barrier [42]. In 2011, there was another study by
Study Number Groups Follow-up Conclusion
Miyake
et al. [41]
118 without
complications
from diabetes
mellitus
1. Fluorometholone
2. Diclofenac
Fundus
fluorescein
angiography
(FFA)
8 weeks
Diclofenac was
effective in prevention
of CME following
cataract surgery
Miyake
et al. [42]
62 1. Fluorometholone
2. Diclofenac
FFA
5 weeks
Diclofenac was more
effective than
fluorometholone in
preventing cystoid
macular edema
Miyake
et al. [43]
60 1. Fluorometholone
2. Nepafenac
OCT
5 weeks
Nepafenac was more
effective than
fluorometholone in
preventing cystoid
macular edema
Nishino
et al. [44]
21 1. Bromfenac
2. Fluorometholone
FFA
1 month
Topical steroid
medication may not be
absolutely essential
after uneventful
phacoemulsification
Weber
et al. [45]
123 1. Indomethacin 0.1%
2. Ketorolac 0.5%
OCT
90 days
Indomethacin 0.1% had
the same effect as
ketorolac 0.5% at first
day postoperative and
more effective than
ketorolac 0.5% at first
week in treating ocular
inflammation after
uncomplicated cataract
surgery. There was no
change from baseline in
retinal thickness in two
groups
Wittpenn
et al. [46]
546 1. Ketorolac 0.4% (only
1 hour prior to
surgery) + prednisolone
for 1 month
2. Ketorolac
0.4 + prednisolone for 1
month
OCT
4–6 weeks
Perioperative ketorolac
to postoperative
prednisolone
significantly reduces
the macular thickening
after cataract surgery
Table 3.
Clinical trials using ophthalmic NSAIDs to prevent postoperative macular edema in a mixed population
(nondiabetic and diabetic patients) without cystoid macular edema preoperatively and with no predisposing
factors for developing cystoid macular edema.
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Miyake et al. which approved that nepafenac was more effective than
fluorometholone in preventing cystoid macular edema [43]. In other hand, some
studies compared the effect of different NSAIDs similar to the study by Cable et al.
who suggested that bromfenac is more effective than nepafenac [38] and Weber
et al. who suggested that there was no change from baseline in retinal thickness
between indomethacin group and ketorolac group.
Nondiabetic patients who have undergone cataract surgery without preoperative
macular edema and with no predisposing factors for developing cystoid macular
edema were enrolled in studies in Table 4. In glaucoma patients after cataract
surgery, Miyake et al. approved that diclofenac seems to prevent macular edema
formation enhanced by latanoprost therapy [49], and timolol and its preservative
benzalkonium chloride [50].
Study Number Groups Follow-
up
Conclusion
Donnenfeld
et al. [47]
100 1. Prednisolone acetate
2. Ketorolac (3 days
preoperative and 3 weeks
postoperative) + prednisolone
3. Ketorolac (1 day preoperative
and 3 weeks
postoperative) + prednisolone
4. Ketorolac (1 hour
preoperative and 3 weeks
postoperative) + prednisolone
OCT
3 months
The preoperative
use of ketorolac
tromethamine 0.4%
for 3 days followed
by 1-day
preoperatively
provided optimum
efficacy and
superior outcomes
relative to 1 hour
preoperatively used
Mathys
et al. [48]
84 1. Nepafenac 0.01% (three
times before
surgery) + prednisolone
acetate 1%
2. Nepafenac 0.01% (three
times before surgery and for
1 month) + prednisolone
acetate 1%
OCT
8 weeks
The increase in
postoperative
macular thickness
was small in both
the control and
treatment groups
Miyake
et al. [49]
80 eyes with
primary open-
angle glaucoma,
normal tension
glaucoma, or
ocular
hypertension
1. Fluorometholone acetate
2. 0.1% diclofenac sodium
FFA
5 weeks
Administration of
nonsteroidal eye
drops such as
diclofenac seems to
prevent macular
edema formation
enhanced by
latanoprost therapy
Miyake
et al. [50]
60 eyes with
primary open-
angle glaucoma,
normal-tension
glaucoma, or
ocular
hypertension
1. 0.1% fluorometholone acetate
2. 0.5% diclofenac sodium
FFA Diclofenac prevents
cystoid macular
edema caused by
timolol and its
preservative,
benzalkonium
chloride
Miyanaga
et al. [51]
72 1. 0.1% betamethasone 1 month,
then 0.1% fluorometholone
1 month
2. 0.1% bromfenac for 2 months
3. 0.1% betamethasone 1 month,
then 0.1% fluorometholone
1 month, and 0.1% bromfenac
twice 2 months
OCT
2 months
There were no
significant
differences in anti-
inflammatory
effects among the
three groups
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Study Number Groups Follow-
up
Conclusion
Moschos
et al. [52]
79 1. Dexamethasone sodium
phosphate 0.1%
2. Dexamethasone sodium
phosphate + diclofenac
sodium 0.1%
OCT
28 days
The addition of
diclofenac did not
seem to offer any
additional benefit
after uneventful
phacoemulsification
Ticly et al.
[53]
91 1. Prednisolone acetate 1%
2. Prednisolone acetate
1% + ketorolac tromethamine
0.4%
FFA
5 weeks
The addition of
ketorolac
tromethamine 0.4%
did not seem to
offer any additional
benefit after
uneventful
phacoemulsification
Wang et al.
[54]
240 1. Oral prednisone tablets 15 mg
for 7 days + fluorometholone
0.1% for 1 month
2. Oral prednisone tablets 15 mg
for 7 days + dexamethasone
0.1% for 1 month
3. Oral prednisone tablets 15 mg
for 7 days + bromfenac 0.1%
for 1 month
4. Oral prednisone tablets 15 mg
for 7 days + bromfenac 0.1%
for 2 months
OCT
2 months
Bromfenac sodium
was more effective
and safer than
fluorometholone
and dexamethasone
as an anti-
inflammatory
Yavas et al.
[55]
189 1. Prednisolone
2. Prednisolone + indomethacin
for 3 days preoperative and
1 month postoperative
3. Prednisolone + indomethacin
for 1 month postoperative
FFA
3 months
Preoperative
nonsteroidal anti-
inflammatory drugs
decreased the
incidence of CME
more than
postoperative use
only
Capote et al.
[56]
243 1. Diclofenac sodium 0.1%
2. Bromfenac 0.09%
3. Nepafenac 0.1%
All received prednisolone 1%
OCT
6 months
Bromfenac is more
effective than
diclofenac and
nepafenac in
reducing macular
thickness after
phacoemulsification
McCafferty
et al. [57]
1000 1. Placebo
2. Nepafenac 0.3%
OCT
FFA
5 weeks
Topical nepafenac
0.3% reduces
macular edema in
patients with
preoperative risk
compared to
placebo, but there
were no differences
in patients without
risk factors
Stock et al.
[58]
77 1. Nepafenac
2. Propylene glycol as control
3. Ketorolac tromethamine
OCT
45 days
There were no
significant
differences in
macular thickness
between the three
groups
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Donnenfeld et al. documented that early started ketorolac 3 days or 1 day
preoperatively provided superior outcomes over ketorolac startes only 1 hour
preoperatively [47]. Also, preoperative indomethacin drugs decreased the incidence
of CME more than postoperative use only in the study of Yavas et al. [55].
In comparative study between different NSAIDs, Capote et al. approved that
bromfenac is more effective than diclofenac and nepafenac in reducing macular
thickness after phacoemulsification [56]. In other study, bromfenac was more
effective and safer in comparison to topical steroid; inspite of using oral prednisones
for all patients in the study [54].
In other studies, NSAIDs did not seem to offer any additional benefit after
uneventful phacoemulsification of diclofenac in the study of Moschos et al. [52] and
ketorolac in the study of Ticly et al. [53]. Miyanaga et al. documented that 2 months'
use of topical NSAIDs, different topical steroids, or alternating steroids and NSAIDs
had no significant differences [51]. Stock et al. suggested no differences between
nepafenac, control, and ketorolac through 45-day follow-up [58].
Mathys et al. told that routine use of preoperative nepafenac may be necessary
to achieve excellent visual recovery if continued for 3 weeks postoperatively or
not [48].
In the study of McCafferty et al., postoperative topical nepafenac reduces mac-
ular edema in patients with preoperative risk (diabetic retinopathy, contralateral
CME, or prostaglandin use) compared to placebo, but there were no differences in
patients without risk factors [57]. Nepafenac was effective in reducing macular
thickness compared with a placebo in fellow eye 5 weeks postoperatively in patients
who had bilateral phacoemulsification enrolled in the study of Tzelikis et al. [60].
7. Conclusion(s)
The most important line of management of postoperative macular edema is by
prevention. NSAIDs have large effects in prevention of postoperative macular
edema with minimal side effects. Furthermore, some studies have suggested that
NSAIDs may have a greater effect in re-establishment of the blood-aqueous barrier
than corticosteroids. The claim about synergistic effects of NSAIDs and corticoste-
roids is made by several authors. Although several studies may have favored
Study Number Groups Follow-
up
Conclusion
Milla et al.
[59]
38 glaucoma
patients
1. Nepafenac group (n = 15)
2. Nonnepafenac group (n = 23)
All received dexamethasone
OCT Nepafenac has a
prophylactic effect
aganist
postoperative
macular edema
Tzelikis
et al. [60]
224 Bilateral cataract was included in
this study
Each patient was assigned randomly
to receive nepafenac 0.3% drops in
one eye and a placebo in the fellow
eye
OCT
12 weeks
Nepafenac 0.3%
was effective in
reducing macular
thickness compared
with a placebo
5 weeks
postoperatively
Table 4.
Clinical trials using ophthalmic NSAIDs to prevent postoperative macular edema in nondiabetic patients
without cystoid macular edema preoperatively and with no predisposing factors for developing cystoid macular
edema.
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starting NSAID treatment preoperatively, there are no comparison studies about
starting corticosteroids preoperatively.
Conflict of interest
The authors declare that they have no conflict of interest.
Author details
Ahmed Alnagdy1*, Ahmed M. Eissa2 and Amr El-Kannishy1
1 Mansoura Ophthalmology Center, Mansoura University, Egypt
2 The General Organization of Teaching Hospitals and Institutes, Egypt
*Address all correspondence to: alnagdy28@gmail.com
©2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
12
Frontiers in Ophthalmology and Ocular Imaging
References
[1]DeBuc D, Somfai G. Early detection
of retinal thickness changes in diabetes
using optical coherence tomography.
Medical Science Monitor. 2010;16:
MT15-MT21
[2]Mentes J, Erakgun T, Afrashi F, Kerci
G. Incidence of cystoid macular edema
after uncomplicated phacoemulsification.
Ophthalmologica. 2003;217:408-412. DOI:
10.1159/000073070
[3] Soliman W, Sander B, Jørgensen T.
Enhanced optical coherence patterns of
diabetic macular oedema and their
correlation with the pathophysiology.
Acta Ophthalmologica. 2007;85:613-617.
DOI: 10.1111/j.1600-0420.2007.00917.x
[4] Lobo C. Pseudophakic cystoid
macular edema. Ophthalmologica. 2012;
227:61-67. DOI: 10.1159/000331277
[5]Miyake K, Ibaraki N. Prostaglandins
and cystoid macular edema. Survey of
Ophthalmology. 2002;47:S203-S218.
DOI: 10.1016/S0039-6257(02)00294-1
[6] Krepler K, Biowski R, Schrey S,
Jandrasits K, Wedrich A. Cataract
surgery in patients with diabetic
retinopathy: Visual outcome, progression
of diabetic retinopathy, and incidence of
diabetic macular oedema. Graefe’s
Archive for Clinical and Experimental
Ophthalmology. 2002;240:735-738
[7] Schmier JK, Halpern MT, Covert
DW, Matthews GP. Evaluation of costs
for cystoid macular edema among
patients after cataract surgery. Retina.
2007;27:621-628
[8] Sawides L, de Castro A, Burns S. The
organization of the cone photoreceptor
mosaic measured in the living human
retina. Vision Research. 2016;132:34-44.
DOI: 10.1016/j.visres.2016.06.006
[9] Spaide R, Klancnik J, Cooney M.
Retinal vascular layers imaged by
fluorescein angiography and optical
coherence tomography angiography.
JAMA Ophthalmology. 2015;133:45-50.
DOI: 10.1001
[10] Ramírez J, Rojas B, Gallego B,
García-Martín E, Triviño A, Ramírez A,
et al. Glia and blood-retinal barrier:
Effects of ocular hypertension. In:
Cardiovascular Disease II. Hong Kong:
Concept Press. 2014. pp. 123-162
[11] Cunha-Vaz J, Bernardes R, Lobo C.
Blood-retinal barrier. European Journal
of Ophthalmology. 2010;21:S3-S9. DOI:
10.1371/journal.pone.0095420
[12]Hori S, Ohtsuki S, Hosoya K,
Nakashima E, Terasaki T. A pericyte-
derived angiopoietin-1 multimeric
complex induces occludin gene
expression in brain capillary endothelial
cells through tie-2 activation in vitro.
Journal of Neurochemistry. 2004;89:
503-513. DOI: 10.1111/
j.1471-4159.2004.02343.x
[13] Runkle E, Antonetti D. The blood-
retinal barrier: Structure and functional
significance. In: Nag S, The Blood-Brain
and Other Neural Barriers: Reviews and
Protocols. Totowa, NJ: Humana Press,
Springer. 2011. pp. 133-148. https://doi.
org/10.1007/978-1-60761-938-3_5
[14]Miyoshi J, Takai Y. Molecular
perspective on tight-junction assembly
and epithelial polarity. Advanced Drug
Delivery Reviews. 2005;57:815-855. DOI:
10.1016/j.addr.2005.01.008
[15]Hee M, Izatt J, Swanson E, Huang D,
Schuman J, Lin C, et al. Optical
coherence tomography of the human
retina. Archives of Ophthalmology.
1995;113:325-332. DOI: 10.1001/
archopht.1995.01100030081025
[16]Gulkilik G, Kocabora S, Taskapili M,
Engin G. Cystoid macular edema after
phacoemulsification: Risk factors and
13
Topical NSAIDs in Prevention of Postcataract Macular Edema
DOI: http://dx.doi.org/10.5772/intechopen.82321
effect on visual acuity. Canadian Journal
of Ophthalmology. 2006;41:699-703.
DOI: 10.3129/i06-062
[17]Ursell P, Spalton D, Whitcup S,
Nussenblatt R. Cystoid macular edema
after phacoemulsification: Relationship
to blood–aqueous barrier damage
and visual acuity. Journal of Cataract
and Refractive Surgery. 1999;25:
1492-1497. DOI: 10.1016/S0886-3350
(99)00196-0
[18] Kičová N, Bertelmann T, Irle S,
Sekundo W, Mennel S. Evaluation of a
posterior vitreous detachment: A
comparison of biomicroscopy, B-scan
ultrasonography and optical coherence
tomography to surgical findings with
chromodissection. Acta
Ophthalmologica. 2012;90:e264-e268.
DOI: 10.1111/j.1755-3768.2011.02330.x
[19] Vukicevic M, Gin T, Al-Qureshi S.
Prevalence of optical coherence
tomography-diagnosed postoperative
cystoid macular oedema in patients
following uncomplicated phaco-
emulsification cataract surgery. Clinical
& Experimental Ophthalmology. 2012;
40:282-287. DOI: 10.1111/
j.1442-9071.2011.02638.x
[20]Muscat S, Parks S, Kemp E, Keating
D. Repeatability and reproducibility of
macular thickness measurements with
the Humphrey OCT system.
Investigative Ophthalmology & Visual
Science. 2002;43:490-495
[21]Degenring R, Vey S, Kamppeter B,
Budde W, Jonas J, Sauder G. Effect of
uncomplicated phacoemulsification on
the central retina in diabetic and non-
diabetic subjects. Graefe's archive for.
Clinical and Experimental
Ophthalmology. 2007;245:18-23
[22] Cho H, Wolf K, Wolf E.
Management of ocular inflammation
and pain following cataract surgery:
Focus on bromfenac ophthalmic
solution. Clinical Ophthalmology. 2009;
3:199-210
[23] Polansky J, Weinreb R. Anti-
inflammatory agents. In: Pharmacology
of the Eye. Berlin, Heidelberg: Springer;
1984. pp. 459-538. https://doi.org/
10.1007/978-3-642-69222-2_11
[24]McGhee C, Dean S, Danesh-Meyer
H. Locally administered ocular
corticosteroids. Drug Safety. 2002;25:
33-55
[25]O’Brien T. Emerging guidelines for
use of NSAID therapy to optimize
cataract surgery patient care. Current
Medical Research and Opinion. 2005;21:
1131-1137. DOI: 10.1185/
030079905X50651
[26]Drugs@FDA [Internet]. 2018.
Rockville (MD): Food and Drug
Administration (US), Center for Drug
Evaluation and Research. Available
from: http://www.accessdata.fda.gov/sc
ripts/cder/drugsatfda/index.cfm [cited:
July 2018]
[27]Heier J, Topping T, Baumann W,
Dirks M, Chern S. Ketorolac versus
prednisolone versus combination
therapy in the treatment of acute
pseudophakic cystoid macular edema.
Ophthalmology. 2000;107:2034-2038.
DOI: 10.1016/S0161-6420(00)00365-1
[28] Alnagdy A, Abouelkheir H, El-
Khouly S, Tarshouby S. Impact of
topical nonsteroidal anti-inflammatory
drugs in prevention of macular edema
following cataract surgery in diabetic
patients. International Journal of
Ophthalmology. 2018;11(4):616-622.
DOI: 10.18240/ijo.2018.04.133738
[29]Gaynes B, Fiscella R. Topical
nonsteroidal anti-inflammatory drugs
for ophthalmic use. Drug Safety. 2002;
25:233-250
[30]Hernández-Díaz S, Rodríguez LAG.
Association between nonsteroidal anti-
14
Frontiers in Ophthalmology and Ocular Imaging
inflammatory drugs and upper
gastrointestinal tract bleeding/
perforation: An overview of
epidemiologic studies published in the
1990s. Archives of Internal Medicine.
2000;160:2093-2099. DOI: 10.1001/
archinte.160.14.2093
[31] Canto MG, Andreu I, Fernandez J,
Blanca M. Selective immediate
hypersensitivity reactions to NSAIDs.
Current Opinion in Allergy and Clinical
Immunology. 2009;9:293-297. DOI:
10.1097/ACI.0b013e32832db943
[32] Sun WH, Tsuji S, Tsujii M,
Gunawan E, Sawaoka H, Kawai N, et al.
Cyclo-oxygenase-2 inhibitors suppress
epithelial cell kinetics and delay gastric
wound healing in rats. Journal of
Gastroenterology and Hepatology.
2000;15:752-761. DOI: 10.1046/
j.1440-1746.2000.02242.x
[33] Sekhar C, Pathapati R, Varalakshmi
U, Harshita S, Patra R, Divyalasya T.
Head-to-head comparison of tolerability
and acceptability of single dose of four
topical NSAIDS in patients undergoing
cataract surgery. Evidence-based
Healthcare. 2015;2:4568-4573. DOI:
10.18410/jebmh/2015/643
[34] Endo N, Kato S, Haruyama K, Shoji
M, Kitano S. Efficacy of bromfenac
sodium ophthalmic solution in
preventing cystoid macular oedema
after cataract surgery in patients with
diabetes. Acta Ophthalmologica. 2010;
88(8):896-900. DOI: 10.1111/
j.1755-3768.2009.01582.x
[35] Singh R, Alpern L, Jaffe G, et al.
Evaluation of nepafenac in prevention
of macular edema following cataract
surgery in patients with diabetic
retinopathy. Clinical Ophthalmology.
2012;6(1):1259-1269. DOI: 10.2147/
OPTH.S31902. PMCID: PMC3422154
[36] Almeida D, Johnson D, Hollands H,
et al. Effect of prophylactic nonsteroidal
antiinflammatory drugs on cystoid
macular edema assessed using optical
coherence tomography quantification of
total macular volume after cataract
surgery. Journal of Cataract and
Refractive Surgery. 2008;34(1):64-69.
DOI: 10.1016/j.jcrs.2007.08.034
[37] Almeida D, Khan Z, Xing L, et al.
Prophylactic nepafenac and ketorolac
versus placebo in preventing
postoperative macular edema after
uneventful phacoemulsification. Journal
of Cataract and Refractive Surgery.
2012;38(9):1537-1543. DOI: 10.1016/j.
jcrs.2012.04.034
[38] Cable M. Comparison of bromfenac
0.09% QD to nepafenac 0.1% TID after
cataract surgery: Pilot evaluation of
visual acuity, macular volume, and
retinal thickness at a single site. Clinical
Ophthalmology. 2012;6(1):997-1004.
DOI: 10.2147/OPTH.S32179. PMCID:
PMC3399390
[39] Cervantes-Coste G, Sanchez-Castro
YG, Orozco-Carroll M, Mendoza-
Schuster E, Velasco-Barona C.
Inhibition of surgically induced miosis
and prevention of postoperative
macular edema with nepafenac. Clinical
Ophthalmology. 2009;3(1):219-226
[40] Rossetti L, Bujtar E, Castoldi D,
Torrazza C, Orzalesi N. Effectiveness of
diclofenac eyedrops in reducing
inflammation and the incidence of
cystoid macular edema after cataract
surgery. Journal of Cataract and
Refractive Surgery. 1996;22:794-799.
DOI: 10.1016/S0886-3350(96)80164-7
[41]Miyake K, Masuda K, Shirato S,
et al. Comparison of diclofenac and
fluorometholone in preventing cystoid
macular edema after small incision
cataract surgery: A multicentered
prospective trial. Japanese Journal of
Ophthalmology. 2000;44(1):58-67.
DOI: 10.1016/S0021-5155(99)00176-8
[42]Miyake K, Nishimura K, Harino S,
et al. The effect of topical diclofenac on
15
Topical NSAIDs in Prevention of Postcataract Macular Edema
DOI: http://dx.doi.org/10.5772/intechopen.82321
choroidal blood flow in early
postoperative pseudophakias with
regard to cystoid macular edema
formation. Investigative Ophthalmology
& Visual Science. 2007;48(12):
5647-5652. DOI: 10.1167/iovs.07-0262
[43]Miyake K, Ota I, Miyake G, Numaga
J. Nepafenac 0.1% versus
fluorometholone 0.1% for preventing
cystoid macular edema after cataract
surgery. Journal of Cataract and
Refractive Surgery. 2011;37(9):
1581-1588. DOI: 10.1167/iovs.07-0262
[44]Nishino M, Eguchi H, Iwata A,
Shiota H, Tanaka M, Tanaka T. Are
topical steroids essential after an
uneventful cataract surgery? The
Journal of Medical Investigation. 2009;
56(1–2):11-15. DOI: 10.2152/jmi.56.11
[45]Weber M, Kodjikian L, Kruse F,
Zagorski Z, Allaire C. Efficacy and
safety of indomethacin 0.1% eye drops
compared with ketorolac 0.5% eye
drops in management of ocular
inflammation after cataract surgery.
Acta Ophthalmologica. 2013;91(1):e15-
e21. DOI: 10.1111/j.1755-3768.2012.
02520.x
[46]Wittpenn J, Silverstein S, Heier J,
Kenyon K, Hunkeler J, Randomized
EMA. Masked comparison of topical
ketorolac 0.4% plus steroid vs steroid
alone in low-risk cataract surgery
patients. American Journal of
Ophthalmology. 2008;146(4):
554-560. DOI: 10.1016/j.ajo.2008.04.
036. e551
[47]Donnenfeld E, Perry H, Wittpenn J,
Solomon R, Nattis A, Chou T.
Preoperative ketorolac tromethamine
0.4% in phacoemulsification outcomes:
Pharmacokinetic-response curve.
Journal of Cataract and Refractive
Surgery. 2006;32(9):1474-1482. DOI:
10.1016/j.jcrs.2006.04.009
[48]Mathys K, Cohen K. Impact of
nepafenac 0.1% on macular thickness
and postoperative visual acuity after
cataract surgery in patients at low risk
for cystoid macular oedema. Eye
(London, England). 2010;24(1):90-96
[49]Miyake K, Ota I, Maekubo K,
Ichihashi S, Miyake S. Latanoprost
accelerates disruption of the blood-
aqueous barrier and the incidence of
angiographic cystoid macular edema in
early postoperative pseudophakias.
Archives of Ophthalmology. 1999;
117(1):34-40. DOI: 10.1001/
archopht.117.1.34
[50]Miyake K, Ota I, Ibaraki N, et al.
Enhanced disruption of the blood-
aqueous barrier and the incidence of
angiographic cystoid macular edema by
topical timolol and its preservative in
early postoperative pseudophakia.
Archives of Ophthalmology. 2001;
119(3):387-394. DOI: :10.1001/
archopht.119.3.387
[51]Miyanaga M, Miyai T, Nejima R,
Maruyama Y, Miyata K, Kato S. Effect
of bromfenac ophthalmic solution on
ocular inflammation following cataract
surgery. Acta Ophthalmologica. 2009;
87(3):300-305. DOI: 10.1111/
j.1755-3768.2008.01433.x
[52]Moschos M, Chatziralli I, Pantazis P,
Rouvas A, Sergentanis T. Is topical
diclofenac essential before and after
uneventful phacoemulsification cataract
surgery? Journal of Ocular
Pharmacology and Therapeutics. 2012;
28(4):335-339.29. DOI: 10.1089/
jop.2011.0256
[53] Ticly F, Lira R, Zanetti F, Machado
M, Rodrigues G, Arieta C. Prophylactic
use of ketorolac tromethamine in
cataract surgery: A randomized trial.
Journal of Ocular Pharmacology and
Therapeutics. 2014;30(6):495-501. DOI:
10.1089/jop.2013.0214
[54]Wang Q, Yao K, Xu W, et al.
Bromfenac sodium 0.1%,
fluorometholone 0.1% and
16
Frontiers in Ophthalmology and Ocular Imaging
dexamethasone 0.1% for control of
ocular inflammation and prevention of
cystoid macular edema after
phacoemulsification. Ophthalmologica.
2013;229(4):187-194. DOI: 10.1159/
000346847
[55] Yavas G, Ozturk F, Kusbeci T.
Preoperative topical indomethacin to
prevent pseudophakic cystoid macular
edema. Journal of Cataract and
Refractive Surgery. 2007;33(5):804-807.
DOI: 10.1016/j.jcrs.2007.01.033
[56] Capote A, Soto M, Ruiz R, Peláez C,
Vazquez G, OftaCosta G, et al.
Comparative study of the efficacy and
safety of bromfenac, nepafenac and
diclofenac sodium for the prevention of
cystoid macular edema after
phacoemulsification. International
Journal of Ophthalmology. 2018;11(7):
1210. DOI: 10.18240/ijo.2018.07.22
[57]McCafferty S, Harris A, Kew C,
Kassm T, Lane L, Levine J, et al.
Pseudophakic cystoid macular edema
prevention and risk factors; prospective
study with adjunctive once daily topical
nepafenac 0.3% versus placebo. BMC
Ophthalmology. 2017;17(1):16. DOI:
10.1186/s12886-017-0405-7
[58] Stock A, Galvan K, Godoy R,
Bonamigo L. Comparison of macular
thickness by optical coherence
tomography measurements after
uneventful phacoemulsification using
ketorolac tromethamine, nepafenac, vs
a control group, preoperatively and
postoperatively. Clinical
Ophthalmology. 2018;12:607. DOI:
10.2147/OPTH.S157738
[59]Milla E, Stirbu O, Franco J,
Hernández G, Rios J, Duch S. Effect of
nepafenac on the foveal profile of
glaucomatous patients undergoing
phacoemulsification. International
Ophthalmology. 2017;37(5):1147-1153
[60] Tzelikis P, Morato C, Neves N, Hida
W, Alves M. Intraindividual comparison
of nepafenac 0.3% for the prevention of
macular edema after phacoemulsification.
Journal of Cataract & Refractive Surgery.
2018;44(4):440-446. DOI: 10.1016/j.
jcrs.2018.01.026
17
Topical NSAIDs in Prevention of Postcataract Macular Edema
DOI: http://dx.doi.org/10.5772/intechopen.82321
